Patents Assigned to Pharmacyclics, Inc.
  • NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
    Publication number: 20120064032
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: August 12, 2011
    Publication date: March 15, 2012
    Applicant: Pharmacyclics, Inc.
    Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20120065201
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • BTK INHIBITORS FOR THE TREATMENT OF IMMUNE MEDIATED CONDITIONS
    Publication number: 20120053189
    Abstract: Disclosed herein are pharmaceutical dosage forms of Brutons tyrosine kinase (Btk) inhibitors. Methods for the preparation of the compounds are disclosed. Methods of using the pharmaceutical dosage forms are disclosed for the treatment of immune mediated conditions and inflammatory diseases or conditions.
    Type: Application
    Filed: June 28, 2011
    Publication date: March 1, 2012
    Applicant: Pharmacyclics, Inc.
    Inventor: David J. Loury
  • Inhibitors of brutons tyrosine kinase
    Patent number: 8088781
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: January 3, 2012
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan, Tarak D. Mody
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20110311624
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: April 16, 2010
    Publication date: December 22, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: David J. LOURY, Joseph J. BUGGY, Tarak D. MODY, Erik J. VERNER, Norbert PURRO, Sriram BALASUBRAMANIAN
  • Inhibitors of tyrosine kinases and uses thereof
    Patent number: 8067395
    Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: November 29, 2011
    Assignee: Pharmacyclics, Inc.
    Inventors: Orion D. Jankowski, James T. Palmer, Lee Honigberg
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20110281322
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: June 16, 2011
    Publication date: November 17, 2011
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS
    Publication number: 20110269806
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: May 3, 2011
    Publication date: November 3, 2011
    Applicant: Pharmacyclics, Inc.
    Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young
  • Hydroxamates as therapeutic agents
    Patent number: 8026371
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: September 27, 2011
    Assignee: Pharmacyclics, Inc.
    Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson
  • INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS
    Publication number: 20110224235
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: July 16, 2009
    Publication date: September 15, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Joseph Buggy, David Loury, Wei Chen
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8008309
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: August 30, 2011
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • FACTOR VIIA INHIBITOR
    Publication number: 20110207939
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: May 3, 2011
    Publication date: August 25, 2011
    Applicant: Pharmacyclics, Inc.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20110184001
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 28, 2011
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS
    Publication number: 20110150825
    Abstract: Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of pro-inflammatory cytokines by administering an HDAC8-selective inhibitor compound. Further described herein are methods for predicting responsiveness to treatments for inflammatory conditions. Methods for predicting efficacy of treatments for inflammatory conditions are also described.
    Type: Application
    Filed: November 14, 2007
    Publication date: June 23, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Susanne M. Steggerda
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 7960396
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: June 14, 2011
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20110086866
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Application
    Filed: October 12, 2010
    Publication date: April 14, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Erik Verner, Mark Stephen Smyth, Wenchen Luo
  • METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS
    Publication number: 20110053164
    Abstract: Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions.
    Type: Application
    Filed: October 5, 2010
    Publication date: March 3, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian
  • Texaphyrin solutions and pharmaceutical formulations
    Publication number: 20110046100
    Abstract: A packaging system is described for a drug that provides protection from contamination, crystallization and/or degradation of the drug during storage of the system prior to its use. The packaging of the drug does not significantly absorb, react with, or otherwise adversely affect the therapeutic effectiveness of the drug or other excipients or components during storage of the system prior to its use. The packaging system is also used for preserving a drug, particularly a drug containing high-purity texaphyrin metal complexes, by providing a product packaging system that prevents, limits or otherwise controls degradation reactions that can result from exposure to oxygen and/or light.
    Type: Application
    Filed: November 4, 2010
    Publication date: February 24, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Norbert Purro, Hugo Madden, Suzanne Kretchmar Nguyen
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20110039868
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: October 19, 2010
    Publication date: February 17, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
    Publication number: 20110021528
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 27, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson